New CEO Tobin, Three Approvals Signal Smoother Times For Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific used the opportunity of its annual March meeting with analysts to announce the selection of James Tobin as the next CEO, a move aimed at allaying the financial community's ongoing concerns about the firm's management and direction.
You may also be interested in...
Medinol Suit Reveals Alleged Schism Among Boston Scientific Topsiders
Pressure is mounting for Boston Scientific to address the apparent rift between its senior-most executives, a division brought to light amidst a growing list of questions relating to the firm's relationship with Israeli stent partner Medinol.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.